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Introduction {#sec1}
============

Hematopoiesis critically depends on hematopoietic stem cells (HSCs), which possess unique self-renewal capacity and multilineage differentiation potential, replenishing all blood lineages ([@bib45]). Acute myeloid leukemia (AML) is an aggressive clonal disorder of hematopoietic stem and progenitor cells (HSPCs) in which the acquisition of mutations by HSPCs results in a block in their myeloid differentiation and the generation of self-renewing leukemic stem cells (LSCs) ([@bib8]). LSCs initiate and propagate the disease, and given that they are treatment resistant, they often fuel disease relapses. Therefore, identification of specific therapeutic targets for LSC elimination is an unmet clinical need.

Emerging evidence indicates an involvement of mRNA N6-methyladenosine (m^6^A) modification, the most abundant internal mRNA modification ([@bib7], [@bib46]), in hematopoietic specification, differentiation, and pathogenesis of AML ([@bib2], [@bib33], [@bib63], [@bib70], [@bib76]). The m^6^A modification is deposited by the m^6^A methyltransferase complex (m^6^A writer) composed of a METTL3 and METTL14 heterodimeric enzymatic core and their regulator, WTAP ([@bib4], [@bib36], [@bib48], [@bib61], [@bib67]), and reversed by m^6^A demethylases (FTO and AlkBH5; [@bib24], [@bib78]) referred to as m^6^A erasers. Recent studies revealed the requirement for METTL3, METTL14, and FTO in leukemic transformation and established the importance of m^6^A modification in AML ([@bib2], [@bib33], [@bib63], [@bib70]). However, while m^6^A modification regulates mRNA processing, translation, and degradation ([@bib13]), the functional contributions of these m^6^A-dependent processes to leukemic transformation have not been explored.

The outcome of RNA m^6^A modification is executed by the YTH (YT521-B homology) domain proteins (known as readers), including nuclear YTHDC1 ([@bib72], [@bib74]) and cytoplasmic YTHDF1--YTHDF3 and YTHDC2 ([@bib54], [@bib58], [@bib66], [@bib68]). Nuclear YTHDC1 regulates mRNA splicing and nuclear export ([@bib72]). While YTHDF1 and YTHDF3 binding to m^6^A enhances mRNA translation ([@bib54], [@bib68]), YTHDF2 recognizes m^6^A mRNA within the GACU/A consensus to mediate degradation of m^6^A transcripts ([@bib10], [@bib68]). Although previous studies perturbing the whole m^6^A pathway have established its significance in AML pathogenesis ([@bib2], [@bib33], [@bib63], [@bib70]), the functions of specific m^6^A readers in leukemia remain unexplored. However, recent studies implicated *Ythdf2* in the regulation of HSC homeostasis and hematopoietic regeneration ([@bib34], [@bib69]). Here, we reveal that targeting YTHDF2 extends the half-life of m^6^A-modified transcripts to selectively compromise AML initiation and propagation without derailing normal hematopoiesis.

Results {#sec2}
=======

*Ythdf2* Is Essential for LSC Development and AML Initiation {#sec2.1}
------------------------------------------------------------

We found that *YTHDF2* was expressed significantly higher across AML samples with diverse cytogenetic abnormalities compared to non-leukemic controls ([Figure 1](#fig1){ref-type="fig"}A), and YTHDF2 protein was highly expressed in primary AML samples ([Figure 1](#fig1){ref-type="fig"}B). We next compared *YTHDF2* expression in datasets from AML cells with LSC activity and AML cells without LSC activity validated by xenotransplantation ([@bib44]) and found that *YTHDF2* expression correlated with LSC activity ([Figure 1](#fig1){ref-type="fig"}C). Given that the majority of CD34^+^ and a minority of CD34^−^ fractions have LSC activity ([@bib11], [@bib53]), we also compared *YTHDF2* expression between these fractions and found that *YTHDF2* was expressed at higher levels in CD34^+^ fractions ([Figure S1](#mmc1){ref-type="supplementary-material"}A). To investigate the requirement for YTHDF2 in leukemogenesis, we employed conditional genetics and a mouse AML model in which *Meis1* and *Hoxa9*, oncogenes frequently overexpressed in human AML ([@bib9], [@bib32]), drive leukemogenesis. In this model ([Figure 1](#fig1){ref-type="fig"}D), HSPCs are transduced with retroviruses co-expressing *Meis1* and *Hoxa9* and serially replated, generating preleukemic cells, which upon transplantation to recipient mice generate self-renewing LSCs, causing AML ([@bib16], [@bib30], [@bib64]). We utilized the conditional and reporter *Ythdf2*^fl^ mouse allele in which exon 2 of *Ythdf2* was flanked by *loxP* sites and GFP was inserted after the start codon of *Ythdf2* in exon 1, generating a fully functional GFP-YTHDF2 fusion protein ([@bib23]). We combined the *Ythdf2*^fl^ allele with *Vav-iCre* ([@bib6]) to generate *Ythdf2*^fl/fl^;*Vav-iCre* (*Ythdf2*^CKO^) mice in which *Ythdf2* is specifically deleted in the hematopoietic system shortly after the emergence of HSCs ([Figures 1](#fig1){ref-type="fig"}E and 1F). *Ythdf2*^CKO^ and control *Ythdf2*^fl/fl^ (*Ythdf2*^CTL^) mice showed normal Mendelian distribution (*Ythdf2*^fl/fl^ × *Ythdf2*^fl/fl^;*Vav-iCre* matings resulted in 65 *Ythdf2*^CTL^ and 47 *Ythdf2*^CKO^ mice at weaning; p = 0.28) and had comparable survival. We transduced *Ythdf2*^CKO^ and *Ythdf2*^CTL^ HSPCs with *Meis1*-*Hoxa9* retroviruses and found that while *Ythdf2*^CKO^ cells produced significantly lower colony numbers upon serial replating ([Figure 1](#fig1){ref-type="fig"}G), they had unaffected expression of c-Kit, CD11b, and Gr-1 ([Figure 1](#fig1){ref-type="fig"}H). Notably, *Ythdf2*-deficient preleukemic cells generated AML with substantially longer latency compared to control cells ([Figures 1](#fig1){ref-type="fig"}I and 1J). The loss of YTHDF2 expression was confirmed in *Ythdf2*^CKO^ cells isolated from moribund recipient mice ([Figure 1](#fig1){ref-type="fig"}K). To enumerate LSCs in the leukemic recipients of *Meis1*-*Hoxa9*-transduced *Ythdf2*^CKO^ and *Ythdf2*^CTL^ cells, we performed a limiting dilution assay with donor-derived CD45.2^+^ bone marrow (BM) cells isolated from primary recipients. We found that LSC frequency in recipients of *Ythdf2*^CKO^ cells was significantly decreased ([Figure 1](#fig1){ref-type="fig"}L). Therefore, *Ythdf2* is required for LSC development and AML initiation.Figure 1*YTHDF2* Is Upregulated in Different AML Subtypes and Is Essential for AML Development(A) *YTHDF2* gene expression in control (CTL) and different cytogenetic subgroups of human AML bone marrow samples. Violin plots show the distribution of log~2~ expression values. Horizontal line in the boxplots indicates median. CNG, cytologically normal with good prognosis; CNI, cytologically normal with intermediate prognosis; CAO, cytologically abnormal not otherwise specified.(B) Western blot of YTHDF2 in normal human CD34^+^ cells and AML samples (karyotype details are shown in [STAR Methods](#sec4){ref-type="sec"}) (left). α-Histone 3 (H3) was used as a loading control. Quantification of YTHDF2 normalized to H3 expression is presented (right).(C) *YTHDF2* gene expression in primitive AML cell compartments with (LSC^+^) and without (LSC^−^) leukemic engraftment potential.(D) Control *Ythdf2*^fl/fl^ (*Ythdf2*^CTL^) and *Ythdf2*^fl/fl^;*Vav-iCre* (*Ythdf2*^CKO^) fetal liver (FL) c-Kit^+^ cells were co-transduced with *Meis1* and *Hoxa9* retroviruses and serially replated. c-Kit^+^ preleukemic cells were transplanted into recipient mice (n = 12--14).(E) A representative histogram showing GFP-YTHDF2 protein expression in *Ythdf2*^CTL^ FL LSK cells and the lack of GFP-YTHDF2 expression in *Ythdf2*^CKO^ FL LSK cells.(F) Percentage of GFP-positive cells in the 14.5 days post coitum (dpc) FL LSK cell population from FLs of *Ythdf2*^CTL^ and *Ythdf2*^CKO^ embryos (n = 5).(G) CFC counts at each replating (n = 3).(H) Percentage of CD11b^+^Gr-1^−^, CD11b^+^Gr-1^+^, and c-Kit^+^ cells in the preleukemic cell compartment (n = 4--5).(I) Percentage of CD45.2^+^ leukemic cells in the PB of recipient mice (n = 12--14 per genotype).(J) Survival curve of recipients transplanted with preleukemic cells (n = 12--14).(K) Percentage of GFP-positive cells in the CD45.2^+^ cell population from moribund recipients of *Ythdf2*^CTL^ and *Ythdf2*^CKO^ cells (n = 5--6).(L) Limiting dilution assay (LDA). Secondary recipients (n = 5--8) were transplanted with indicated doses of CD45.2^+^ BM cells from primary recipients.(M) *Ythdf2*^CTL^ and *Ythdf2*^CKO^ FL c-Kit^+^ cells were transduced with *MOZ-TIF2* or *PML-RARA* retroviruses and serially replated. CFC counts at each replating are shown (n = 3).Data represent mean ± SEM; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗∗^p \< 0.0001.

To test whether *Ythdf2* is required for leukemic transformation driven by other oncogenes, we used PML-RARA, which causes acute promyelocytic leukemia, and MOZ-TIF2, which is associated with AML with inv(8)(p11q13). Serial replating assays revealed that *Ythdf2*^CKO^ c-Kit^+^ cells transduced with either PML-RARA or MOZ-TIF2 retroviruses failed to efficiently generate colonies ([Figure 1](#fig1){ref-type="fig"}M). Thus, *Ythdf2* is essential for leukemic transformation driven also by other oncogenes.

*Ythdf2* Is Critical for AML Propagation {#sec2.2}
----------------------------------------

We next asked whether acute deletion of *Ythdf2* from established LSCs using *Mx1-Cre* impacts LSC maintenance and leukemia propagation. We generated experimental *Ythdf2*^fl/fl^*;Mx1-Cre* (*Ythdf2*^iCKO^) and control *Ythdf2*^fl/fl^ (*Ythdf2*^CTL^) mice, transduced HSPCs with *Meis1*-*Hoxa9* retroviruses, and transplanted them into lethally irradiated primary recipients ([Figure 2](#fig2){ref-type="fig"}A). Upon leukemia development, c-Kit^+^ cells (a population enriched for LSCs; [@bib55]) were isolated, and given the leakiness of *Mx1-Cre* upon transplantation ([@bib62]), the population was further sorted for GFP^+^ cells to enrich for those expressing YTHDF2 ([Figure 2](#fig2){ref-type="fig"}B). While *Ythdf2*^CTL^ c-Kit^+^GFP^+^ cells showed significant engraftment and caused aggressive AML in secondary recipients ([Figures 2](#fig2){ref-type="fig"}C and 2D), *Ythdf2*^iCKO^ c-Kit^+^GFP^+^ cells lost YTHDF2 expression ([Figure 2](#fig2){ref-type="fig"}E) due to spontaneous *Mx1-Cre* activation (even without the administration of polyinosinic-polycytidylic acid \[pIpC\]) and failed to efficiently engraft and propagate the disease ([Figures 2](#fig2){ref-type="fig"}C and 2D). Therefore, YTHDF2 is critical for LSC maintenance.Figure 2Loss of YTHDF2 from Established LSCs and Human AML Cells Compromises Their Ability to Propagate AML(A) *Ythdf2*^fl/fl^ (*Ythdf2*^CTL^) and *Ythdf2*^fl/fl^;*Mx1-Cre* (*Ythdf2*^iCKO^) FL c-Kit^+^ cells were co-transduced with *Meis1* and *Hoxa9* retroviruses, serially replated, and transplanted into primary recipients. GFP^+^c-Kit^+^CD45.2^+^ cells sorted from leukemic primary recipients were re-transplanted into secondary recipients (n = 14--16).(B) Percentage of GFP-expressing cells as a measure of YTHDF2 expression in *Ythdf2*^CTL^ and *Ythdf2*^iCKO^ leukemic cells prior to secondary transplantation.(C) Percentage of CD45.2^+^ leukemic cells in the PB of the secondary recipient mice 3 weeks after transplantation (n = 14--16 recipients).(D) Survival curve of mice transplanted with *Ythdf2*^CTL^ and *Ythdf2*^iCKO^ leukemic cells (n = 14--16 mice).(E) Percentage of GFP-expressing cells in PB CD45.2^+^ cell compartment of secondary recipient mice.(F) Left: relative levels of *YTHDF2* mRNA (normalized to *HPRT1*) in human AML THP-1 cells transduced with lentiviruses expressing scrambled short hairpin RNA (shRNA) (CTL) and two independent shRNAs targeting *YTHDF2* (KD1 and KD2); n = 3. Right: western blot of YTHDF2 in THP-1 cells shown on the left. α-Histone 3 (H3) was used as a loading control.(G) Proliferation assays with THP-1 cells with CTL, KD1, and KD2 shRNAs.(H) Percentage of Annexin V^+^DAPI^−^ cells.(I) Percentage of CD11b^−^CD14^−^, CD11b^+^CD14^−^, CD11b^+^CD14^+^, and CD11b^−^CD14^+^ cells in cultures shown in (G) and (H).(J) NSG mice were injected with THP-1 cells transduced with CTL (n = 4) or KD (n = 4) lentiviruses and analyzed 1 month later. Percentage of human CD45^+^CD33^+^ cells in the BM, liver, spleen, and PB of the recipient mice is shown.(K) Survival curve of mice transplanted with 10,000 (n = 6) and 1,000 (n = 3) THP-1 cells.(L) Three independent human primary AML samples (AML1--AML3; detailed in [STAR Methods](#sec4){ref-type="sec"}) were transduced with CTL, KD1, and KD2 lentiviruses. The graph shows AML-CFC frequencies after 7 days of culture (n = 3 technical replicates per sample).(M) Representative colony images from (L).Data represent mean ± SEM in (A)--(K) or mean ± SD in (L)--(M); ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.

Targeting YTHDF2 Disables Human AML Cells {#sec2.3}
-----------------------------------------

To investigate the requirement for YTHDF2 in human leukemic cells, we knocked down the expression of *YTHDF2* in human AML THP-1 cells harboring MLL-AF9 translocation using two independent short hairpins targeting *YTHDF2*. *YTHDF2* knockdown ([Figure 2](#fig2){ref-type="fig"}F) inhibited their proliferative capacity ([Figure 2](#fig2){ref-type="fig"}G) and increased their apoptosis ([Figure 2](#fig2){ref-type="fig"}H) but had no impact on their myeloid differentiation ([Figure 2](#fig2){ref-type="fig"}I). This finding was corroborated in NOMO-1 AML cells harboring MLL-AF9 translocation ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). THP-1 cells with *YTHDF2* knockdown had compromised capacity to engraft AML ([Figure 2](#fig2){ref-type="fig"}J) and displayed impaired ability to cause fatal AML ([Figure 2](#fig2){ref-type="fig"}K). Finally, we performed knockdown experiments in independent human primary AML samples and found that *YTHDF2* depletion significantly decreased the clonogenic potential of AML cells in colony-forming cell (CFC) assays ([Figures 2](#fig2){ref-type="fig"}L and 2M). Thus, YTHDF2 is necessary for human AML cell survival and leukemic cell engraftment.

*Ythdf2* Deletion Does Not Derail Normal Hematopoiesis {#sec2.4}
------------------------------------------------------

We next investigated whether *Ythdf2* deletion has any detrimental effects on HSC functions and multilineage hematopoiesis. To determine the YTHDF2 expression at different levels of the hematopoietic differentiation hierarchy, we employed *Ythdf2*^fl/fl^ mice harboring the GFP-YTHDF2 fusion protein ([@bib23]). All hematopoietic cells in adult BM expressed GFP-YTHDF2 ([Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). YTHDF2 was highly expressed in Lin^−^Sca-1^+^c-Kit^+^ (LSK) stem and/or progenitor cells, HSCs, multipotent progenitors (MPPs), primitive hematopoietic progenitors (HPC-1 and HPC-2 populations), and myeloid progenitors, and its expression was decreased in differentiated Lin^+^ cells ([Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A).Figure 3*Ythdf2* Deletion Results in HSC and Progenitor Cell Expansion and Enhanced HSC Reconstitution Potential(A) GFP expression in the BM cell populations from 8- to 12-week-old *Ythdf2*^fl/fl^ (*Ythdf2*^CTL^) mice. YTHDF2 is uniformly expressed in BM Lin^−^Sca-1^+^c-Kit^+^ (LSK) cells, LSKCD48^−^CD150^+^ HSCs, LSKCD48^−^CD150^−^ multipotent progenitors (MPPs), primitive hematopoietic progenitor cells (i.e., LSKCD48^+^CD150^−^ HPC-1 and LSKCD48^+^CD150^+^ HPC-2 populations), and Lin^−^Sca-1^−^c-Kit^+^ (LK) myeloid progenitors, and its expression is decreased in differentiated Lin^+^ cells. Data represent mean fluorescence intensity (MFI) ± SEM (n = 4).(B) PB counts of *Ythdf2*^CTL^ and *Ythdf2*^CKO^ in 8- to 10-wk-old mice (n = 8--9).(C) CFU assays performed with BM cells from 8- to 10-wk-old mice. CFU-Red, CFU-erythroid and/or megakaryocyte; CFU-G, CFU-granulocyte; CFU-M, CFU-monocyte/macrophage; CFU-GM, CFU--granulocyte and monocyte/macrophage; CFU-Mix, at least three of the following: granulocyte, erythroid, monocyte/macrophage, and megakaryocyte (n = 4).(D) FACS profiles showing frequencies (± SEM) of BM LSK, HSC, MPP, HPC-1, and HPC-2 cell populations from *Ythdf2*^CTL^ and *Ythdf2*^CKO^ mice (n = 6--7 mice).(E) Total number of BM cell populations presented in (D).(F) *Ythdf2*^fl/fl^*;Mx1-Cre* (*Ythdf2*^iCKO^) and control *Ythdf2*^fl/fl^ (*Ythdf2*^CTL^) mice were injected with pIpC and analyzed 3 months after the last injection.(G) Graph showing the percentage of GFP-positive cells in BM of pIpC-treated *Ythdf2*^iCKO^ and *Ythdf2*^CTL^ mice (n = 10--12).(H) Total BM cellularity of pIpC-treated *Ythdf2*^iCKO^ and *Ythdf2*^CTL^ mice.(I) Total cell numbers of BM monocytes, granulocytes, and B cells.(J) Total cell numbers of BM LSK and LK cell populations.(K) HSCs were transplanted into lethally irradiated recipient mice (n = 6--9) together with competitor BM cells. Graph shows the percentage of CD45.2^+^ cells overall in the PB and in the monocyte, granulocyte, B cell, and T cell compartments of the PB of primary recipients.(L and M) Percentage of CD45.2^+^ cells in the Lin^+^, Lin^−^, LK, LSK, and HSC (L) and differentiated (M) cell compartments in the BM of recipient mice.Data represent mean ± SEM; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.

Peripheral blood (PB) analyses of *Ythdf2*^CKO^ mice revealed modest decreases in numbers of white blood cells (WBCs), red blood cells (RBCs), B cells, and CD8^+^ T cells and elevated platelet levels ([Figure 3](#fig3){ref-type="fig"}B). Apart from a decrease in CD8^+^ T cells, *Ythdf2*^CKO^ mice had essentially normal numbers of differentiated cells in their spleens ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We found unaffected numbers of granulocyte/macrophage progenitors (GMPs), increased numbers of pre-megakaryocyte/erythroid progenitors (pre-MegEs) and megakaryocyte progenitors (MkPs) and an imbalance between pre-colony forming unit-erythroid (pre-CFU-E) and colony forming unit-erythroid (CFU-E) ([Figure S2](#mmc1){ref-type="supplementary-material"}C). CFC assays showed normal differentiation potential of *Ythdf2*^CKO^ BM cells ([Figure 3](#fig3){ref-type="fig"}C). Thus, YTHDF2 is not critical for steady-state hematopoiesis.

*Ythdf2* Loss Results in HSC Expansion {#sec2.5}
--------------------------------------

We next investigated the impact of *Ythdf2* deletion on stem and progenitor cells. Adult *Ythdf2*^CKO^ mice displayed expansion of LSK cells, HSCs, and HPC-1 and HPC-2 progenitor cells compared to *Ythdf2*^CTL^ mice ([Figures 3](#fig3){ref-type="fig"}D and 3E). We also inducibly ablated *Ythdf2* using *Mx1-Cre*, which upon pIpC injection acutely deletes *Ythdf2* in *Ythdf2*^iCKO^ adult mice ([Figure 3](#fig3){ref-type="fig"}F). Acute *Ythdf2* deletion ([Figure 3](#fig3){ref-type="fig"}G) had no impact on mouse survival (data not shown) or multilineage hematopoiesis ([Figures 3](#fig3){ref-type="fig"}H and 3I; [Table S1](#mmc1){ref-type="supplementary-material"}) and resulted in increased numbers of LSK cells, but not myeloid progenitor cells ([Figure 3](#fig3){ref-type="fig"}J). Thus, hematopoiesis-specific *Ythdf2* ablation during development or acute deletion in adult mice leads to an expansion of the primitive cell compartment at the top of the hematopoietic hierarchy and does not derail normal hematopoiesis.

To reveal the repopulation capacity of *Ythdf2*-deficient HSCs, we competitively transplanted HSCs from *Ythdf2*^CKO^ and *Ythdf2*^CTL^ mice into lethally irradiated recipients. HSCs of both genotypes gave equal overall long-term reconstitution ([Figure 3](#fig3){ref-type="fig"}K). However, while *Ythdf2*^CKO^ HSCs had enhanced myeloid lineage reconstitution capacity, they had normal B cell and compromised T cell reconstitution potentials ([Figure 3](#fig3){ref-type="fig"}K). Strikingly, *Ythdf2*^CKO^ HSCs displayed significantly increased capacity to contribute to the BM HSC and progenitor cell compartments and differentiated cell compartments ([Figures 3](#fig3){ref-type="fig"}L and 3M). The analyses of donor-derived compartment of the recipients revealed increased frequencies of *Ythdf2*^CKO^ LSK, HPC-1, and HPC-2 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}D). The myeloid bias of *Ythdf2*-deficient HSCs and its connection to a shift in balance among the HSCs, MPP, and HPC populations upon *Ythdf2* deletion merit future investigation. Therefore, targeting *Ythdf2* promotes stem or primitive progenitor cell expansion and enhances their reconstitution and myeloid differentiation potentials.

YTHDF2 Decreases m^6^A RNA Stability in AML {#sec2.6}
-------------------------------------------

We next sought to understand the mechanism by which YTHDF2 loss impedes LSC function. YTHDF2 is known to promote transcript decay through deadenylation ([@bib10], [@bib66]). Indeed, the loss of YTHDF2 resulted in deregulated gene expression with 754 upregulated and 528 downregulated genes; p \< 0.05) in *Ythdf2*^CKO^ compared to *Ythdf2*^CTL^ preleukemic cells ([Figure 4](#fig4){ref-type="fig"}A). Gene Ontology analysis of deregulated genes in preleukemic cells revealed generic metabolic processes in the upregulated genes and immune response processes in the downregulated genes ([Figure S3](#mmc1){ref-type="supplementary-material"}A). To understand which of the deregulated transcripts could be direct targets of YTHDF2, we determined transcriptome-wide mRNA m^6^A in *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells. This revealed the expected m^6^A consensus motif as well as distribution of m^6^A within the transcriptome and enrichment around the stop codon within transcripts in both genotypes ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D). Furthermore, *Ythdf2* deficiency did not alter any of these parameters ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D). YTHDF2 loss is expected to result in the upregulation of direct target transcripts; indeed, we observed an enrichment for m^6^A occupancy in the significantly upregulated genes (p \< 0.05; 754 genes) in *Ythdf2*^CKO^ preleukemic cells compared to the corresponding unchanged or downregulated gene sets ([Figure 4](#fig4){ref-type="fig"}B). Reciprocally, we analyzed the transcriptome based on RNA m^6^A modification and found that transcripts that contain m^6^A show increased expression in *Ythdf2*^CKO^ preleukemic cells ([Figures 4](#fig4){ref-type="fig"}C and 4D). To understand if these observations are extended to the AML *in vivo*, we isolated LSCs from mice with AML derived from *Ythdf2*^*CTL*^ and *Ythdf2*^*CKO*^ preleukemic cells and performed gene expression analysis ([Figure S3](#mmc1){ref-type="supplementary-material"}E). The relationship between m^6^A occupancy and increased transcript dosage was also observed in *Ythdf2*^CKO^ LSCs ([Figures S3](#mmc1){ref-type="supplementary-material"}F--S3H). The upregulation of m^6^A-containing transcripts in the absence of YTHDF2 may arise from an increase in their half-life. We therefore measured mRNA half-life transcriptome-wide in preleukemic cells using thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq; [@bib20]), which revealed an overall modest increase in mRNA half-life in *Ythdf2*^CKO^ cells ([Figure 4](#fig4){ref-type="fig"}E). Interestingly, m^6^A-containing transcripts displayed overall shorter half-lives than non-m^6^A transcripts in *Ythdf2*^*CTL*^ cells ([Figure 4](#fig4){ref-type="fig"}F). YTHDF2 loss extended the half-life of m^6^A-containing transcripts ([Figures 4](#fig4){ref-type="fig"}F and 4G). We next employed ribosome profiling (RIBO-seq; [@bib51]) to measure translational efficiency that did not grossly alter between the respective genotypes ([Figure 4](#fig4){ref-type="fig"}H). YTHDF2 deficiency did not alter the translational efficiency of either m^6^A or non-m^6^A-containing transcripts ([Figure 4](#fig4){ref-type="fig"}I). These data indicate that m^6^A-directed YTHDF2-mediated mRNA decay contributes to the regulation of the leukemic transcriptome.Figure 4YTHDF2 Targets m^6^A-Methylated Transcripts for Degradation(A) Transcript expression scatterplot from *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells (n = 5). Significantly upregulated or downregulated transcripts are highlighted in red (p \< 0.05).(B) m^6^A peak false discovery rate (FDR) (−log~10~Q) in *Ythdf2*^CTL^ preleukemic cells for transcripts grouped according to expression changes between *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells is shown (down, genes significantly downregulated in *Ythdf2*^CKO^ \[p \< 0.05\]; unchanged, genes not significantly changing in *Ythdf2*^CKO^; up, genes significantly upregulated in *Ythdf2*^CKO^ \[p \< 0.05\]). The upper and lower quartiles and the median are shown for each group.(C) Violin plots showing expression change between *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells for not-methylated (no m^6^A), methylated (m^6^A, −log~10~Q ≤ 25), and highly methylated (m^6^A high, −log~10~Q \> 25) transcripts. The upper and lower quartiles and the median are indicated for each group.(D) Cumulative distributions of transcript expression change in *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells for not-methylated, methylated, and highly methylated transcripts as in (C).(E) Mode decay curves for *Ythdf2*^CTL^ (black) and *Ythdf2*^CKO^ (red) preleukemic cell transcriptomes are shown. The shaded areas indicate the first and third quantile decay curves range for each genotype. Transcript half-life modes for each genotype are indicated with horizontal dotted lines and are also shown at the panel top.(F) Cumulative distributions of transcript half-life in *Ythdf2*^CTL^ (left) and *Ythdf2*^CKO^ (right) preleukemic cells are shown for not methylated, methylated and highly methylated transcripts as in (C). The half-life change significance between methylated and not-methylated transcripts is indicated.(G) Cumulative distributions of relative stability change between *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells are shown for not-methylated, methylated, and highly methylated transcripts as in (C). The relative stability change significances between the methylated and not methylated transcripts are indicated.(H) Volcano plot of translational efficiency change between *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells. Not-methylated, methylated, and highly methylated transcripts defined as in (C) are shown in black, green, and red, respectively.(I) Cumulative distributions of translational efficiency of not-methylated (right), methylated (middle), and highly methylated transcripts (left) defined as in (C) are shown for *Ythdf2*^CTL^ (black) and *Ythdf2*^CKO^ (red) preleukemic cells.(J) Violin plots of m^6^A peak FDR (−log~10~*Q*) in MA9.3ITD and NOMO-1 cells for transcripts grouped according to expression changes between *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells as in (B) are shown. The upper and lower quartiles and the median are indicated for each group.(K) CPDB analysis of genes significantly upregulated in *Ythdf2*^CKO^ preleukemic cells (p \< 0.05) with high m^6^A levels (−log~10~*Q* \> 25) in mouse preleukemic cells and also methylated in human AML cell lines.(L) GSEA using LSC signature gene set for genes defined in (K) and that negatively correlate with *YTHDF2* expression in human AML samples.(M) m^6^A immunoprecipitation (IP) read coverage (blue) from *Ythdf2*^CTL^ preleukemic cells along the *Trnfrs1b* genomic locus (top) and m^6^A IP read coverage from NOMO-1, and MA9.3ITD cells along the *TNFRSF1B* genomic locus (bottom) are shown. Input coverage is shown in green.(N) *Tnfrsf1b* enrichment in YTHDF2 immunoprecipitates from *Ythdf2*^CTL^ preleukemic cells is shown. *Tnfrsf1b* background levels were determined using *Ythdf2*^CKO^ preleukemic cells (n = 3).(O) Decay curves for *Trnfrs1b* in *Ythdf2*^CTL^ (top) and *Ythdf2*^CKO^ (bottom) preleukemic cells transcriptomes are shown. The center value and the error bars at each time point indicate the conversion rate mean and SD, respectively. The conversion rates for each biological replicate are indicated with dots. The *Trnfrs1b* half-life is also shown.(P) FACS plots showing the expression of TNFR2 on the cell surface of *Ythdf2*^CTL^ and *Ythdf2*^CKO^ preleukemic cells. The inner graph displays the quantification of TNFR2 expression (n = 4).(Q) Percentage of Annexin V^+^DAPI^−^ preleukemic cells treated with TNF-α at 0-h and 6-h time points (n = 3).Data in (N), (P), and (Q) represent mean ± SEM. In (B), (C), (J), (N), (P), and (Q) ^∗^p \< 0.05; ^∗∗^p \< 0.01.

Next, we sought to determine if the m^6^A-modified transcripts deregulated upon *Ythdf2* deletion in mouse AML are relevant to human AML. We found that transcripts significantly upregulated in the *Ythdf2*^*CKO*^ preleukemic cells are preferentially methylated in human AML cell lines ([Figure 4](#fig4){ref-type="fig"}J). To understand the molecular pathways underpinned by upregulated transcripts methylated both in mouse and human, we performed ConcensusPathDB (CPDB) network analysis and found enrichment for RNA processing, mitochondrial function, ubiquitination as well as tumor necrosis factor (TNF) signaling ([Figures 4](#fig4){ref-type="fig"}K and [S3](#mmc1){ref-type="supplementary-material"}I). To reveal why the loss of YTHDF2 is correlated with a weak leukemogenic potential, we interrogated gene sets from human AML samples associated with different leukemogenic potential in *vivo* ([@bib44]). The upregulated transcripts in *Ythdf2*^CKO^ preleukemic cells that contain m^6^A in both mouse and human AML cells were divided into groups whose expression positively or negatively correlates with YTHDF2 expression in 1,732 human AML samples ([Figure S3](#mmc1){ref-type="supplementary-material"}I). We found that transcripts that negatively correlate with YTHDF2 expression are highly associated with the loss of leukemogenic potential ([Figure 4](#fig4){ref-type="fig"}L). In this way, when an AML sample expresses low amounts of YTHDF2, transcripts associated with the loss of leukemogenic potential have greater expression. In contrast, transcripts whose expression correlates with that of YTHDF2 are depleted from transcripts associated with weak LSC activity ([Figure S3](#mmc1){ref-type="supplementary-material"}J). Thus, YTHDF2 negatively regulates transcripts whose expression limits LSC activity.

*Ythdf2* Deletion Sensitizes AML Cells to TNF {#sec2.7}
---------------------------------------------

Inspecting the genes that negatively correlate with YTHDF2 expression in human AML, contain m^6^A in both mouse and human AML, are upregulated in *Ythdf2*^*CKO*^ LSCs, and are associated with weak LSC function, we found TNF receptor 2 (TNFR2) encoded by *Tnfrsf1b* gene ([Figure 4](#fig4){ref-type="fig"}L). We focused on TNFR2, as TNF signaling was also identified as a node in the CPDB network analysis ([Figure 4](#fig4){ref-type="fig"}K) and TNFR2, together with TNFR1, restricts the accumulation of leukemic cells ([@bib21]). *TNFRSF1B* expression is significantly decreased in AML samples compared to non-leukemic controls ([Figure S3](#mmc1){ref-type="supplementary-material"}K), and its expression negatively correlates with LSC activity ([Figure S3](#mmc1){ref-type="supplementary-material"}L). Notably, *TNFRSF1B* is highly methylated in mouse preleukemic cells and human AML cells ([Figure 4](#fig4){ref-type="fig"}M). RNA immunoprecipitation (RIP)-qPCR revealed co-precipitation of the *Tnfrsf1b* transcript with YTHDF2 ([Figure 4](#fig4){ref-type="fig"}N). Concurrent with the increased half-life of *Tnfrsf1b* transcript ([Figure 4](#fig4){ref-type="fig"}O), the surface expression of TNFR2 is upregulated on *Ythdf2*^*CKO*^ preleukemic cells ([Figure 4](#fig4){ref-type="fig"}P). We therefore tested if TNF stimulation had differential impact on *Ythdf2*^*CTL*^ and *Ythdf2*^*CKO*^ preleukemic cells. YTHDF2 loss rendered cells more sensitive to TNF-induced apoptosis ([Figure 4](#fig4){ref-type="fig"}Q). This highlights at least one molecular mechanism by which YTHDF2 loss negatively impacts AML.

Discussion {#sec3}
==========

Through the analysis of mRNA m^6^A methyltransferases and demethylase, a key role for mRNA m^6^A has been shown in AML pathogenesis ([@bib2], [@bib33], [@bib63], [@bib70]). The modification of mRNA with m^6^A can have multiple outcomes on the respective transcript ([@bib77]), but here we demonstrate that the YTHDF2-mediated component of the pathway is also critical for cancer stem cells in AML. We find that inhibition of YTHDF2 specifically compromises LSC development and propagation. Given the more severe impact of *Ythdf2* deletion or knockdown on established AML compared to disease development, AML propagation may be even more dependent on YTHDF2 than disease initiation. Furthermore, consistent with recent findings in mouse and human HSCs ([@bib34], [@bib69]), we demonstrate that targeting *Ythdf2* expands HSCs and enhances their myeloid reconstitution. These are unique properties of YTHDF2, which, coupled with the fact that the loss of YTHDF2 is permissive in adult mice, underscores the therapeutic potential of YTHDF2 inhibition as a strategy for AML treatment. Such an intervention would have the dual benefits of eradicating malignant LSCs while bestowing a competitive advantage to normal HSCs. Given that isolation of HSCs in sufficient quantities is a limiting factor for the usage of HSC transplantation for a variety of diseases, inhibition of YTHDF2 could be employed to expand HSCs *in vitro* or *in vivo* to circumvent this challenge. In summary, we revealed the m^6^A reader YTHDF2 as a critical mediator of LSCs whose inhibition selectively compromises AML implying its future applications in treatment of this hematological malignancy.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-Mouse CD4 (Biotin conjugated, clone H129.19)BD BiosciencesCat\#553649; RRID: [AB_394969](nif-antibody:AB_394969){#interref180}Anti-Mouse CD5 (Biotin conjugated, clone 53-7.3)BD BiosciencesCat\#553019; RRID: [AB_394557](nif-antibody:AB_394557){#interref185}Anti-Mouse CD8a (Biotin conjugated, clone 53-6.7)BD BiosciencesCat\#553029; RRID: [AB_394567](nif-antibody:AB_394567){#interref190}Anti-Mouse CD11b (Biotin conjugated, clone M1/70)BD BiosciencesCat\#553309; RRID: [AB_394773](nif-antibody:AB_394773){#interref195}Anti-Mouse CD45R/B220 (Biotin conjugated, clone RA3-6B2)BD BiosciencesCat\#553086; RRID: [AB_394616](nif-antibody:AB_394616){#interref200}Anti-Mouse Ter119 (Biotin conjugated, clone TER-119)BD BiosciencesCat\#553672; RRID: [AB_394985](nif-antibody:AB_394985){#interref205}Anti-Mouse Gr-1/Ly-6G/C (Biotin conjugated, clone RB6-8C5)BD BiosciencesCat\#553125; RRID: [AB_394641](nif-antibody:AB_394641){#interref210}Anti-Mouse c-Kit/CD117 (APC-Cy7 conjugated, clone 2B8)BiolegendCat\#105826; RRID: [AB_1626278](nif-antibody:AB_1626278){#interref215}Anti-Mouse c-Kit/CD117 (APC conjugated, clone 2B8)BiolegendCat\#105812; RRID: [AB_313221](nif-antibody:AB_313221){#interref220}Anti-Mouse Sca-1 (PB conjugated, clone E13-161.7)BiolegendCat\#122520; RRID: [AB_2143237](nif-antibody:AB_2143237){#interref225}Anti-Mouse Sca-1 (APC-Cy7 conjugated, clone D7)BiolegendCat\#108125; RRID: [AB_10639725](nif-antibody:AB_10639725){#interref230}Anti-Mouse CD48 (PE conjugated, clone HM48-1)BiolegendCat\#103406; RRID: [AB_313021](nif-antibody:AB_313021){#interref235}Anti-Mouse CD150 (PE-Cy7 conjugated, clone 12F12.2)BiolegendCat\#115914; RRID: [AB_439797](nif-antibody:AB_439797){#interref240}Anti-Mouse CD45R/B220 (PerCP conjugated, clone RA3-6B2)BiolegendCat\#103236; RRID: [AB_893354](nif-antibody:AB_893354){#interref245}Anti-Mouse CD19 (APC-Cy7 conjugated, clone 6D5)BiolegendCat\#115530; RRID: [AB_830707](nif-antibody:AB_830707){#interref250}Anti-Mouse CD11b (PB conjugated, clone M1/70)BiolegendCat\#101224; RRID: [AB_755986](nif-antibody:AB_755986){#interref255}Anti-Mouse CD11b (PE conjugated, clone M1/70)BiolegendCat\#101208; RRID: [AB_312791](nif-antibody:AB_312791){#interref260}Anti-Mouse CD11b (APC conjugated, clone M1/70)BiolegendCat101211; RRID: [AB_312794](nif-antibody:AB_312794){#interref265}Anti-Mouse Gr-1/Ly-6G/C (PE-Cy7 conjugated, clone RB6-8C5)BiolegendCat\#108416; RRID: [AB_313381](nif-antibody:AB_313381){#interref270}Anti-Mouse CD8a (APC conjugated, clone 53-6.7)BiolegendCat\#100712; RRID: [AB_312751](nif-antibody:AB_312751){#interref275}Anti-Mouse CD8a (PE conjugated, clone 53-6.7)BiolegendCat\#100708; RRID: [AB_312747](nif-antibody:AB_312747){#interref280}Anti-Mouse CD4 (PE conjugated, clone H129.19)BiolegendCat\#130310; RRID: [AB_2075573](nif-antibody:AB_2075573){#interref285}Anti-Mouse CD45.1 (BV711 conjugated, clone A20)BiolegendCat\#110739; RRID: [AB_2562605](nif-antibody:AB_2562605){#interref290}Anti-Mouse CD45.2 (PB conjugated, clone 104)BiolegendCat\#109820; RRID: [AB_492872](nif-antibody:AB_492872){#interref295}Anti-Mouse Ter119 (APC conjugated, clone TER-119)eBiosciencesCat\#17-5921; RRID: [AB_469473](nif-antibody:AB_469473){#interref300}Anti-Mouse CD120b/TNFRII (PE conjugated, clone TR75-89)BiolegendCat\#113405; RRID: [AB_2206942](nif-antibody:AB_2206942){#interref305}Anti-human CD45 (PE conjugated, clone 2D1)BiolegendCat\#368509; RRID: [AB_2566369](nif-antibody:AB_2566369){#interref310}Anti-human CD33 (APC conjugated, clone WM53)BiolegendCat\#303407; RRID: [AB_314351](nif-antibody:AB_314351){#interref315}Anti-human CD11b (APC conjugated, clone ICRF44)Biolegend301309; RRID: [AB_314161](nif-antibody:AB_314161){#interref320}Anti-human CD14 (PE conjugated, clone 63D3)Biolegend367103; RRID: [AB_2565887](nif-antibody:AB_2565887){#interref325}Annexin-V (PE conjugated)BD Biosciences556421TO-PRO-3Life TechnologiesCat\#T3605DAPILife TechnologiesCat\#D1306; RRID: [AB_2629482](nif-antibody:AB_2629482){#interref330}Streptavidin (PerCP conjugated)BiolegendCat\#405213Fc Block (clone 2.4G2)BD BiosciencesCat\#553142; RRID: [AB_3946587](nif-antibody:AB_3946587){#interref335}Western blotting α-YTHDF2ProteintechCat\#24744-1-AP; RRID: [AB_2687435](nif-antibody:AB_2687435){#interref340}Western blotting α-Histone 3 (H3)abcamCat\#ab1791; RRID: [AB_302613](nif-antibody:AB_302613){#interref345}**Bacterial and Virus Strains**MSCV-Meis1a-puroGift from Tim Somerville[@bib56]MSCV-Hoxa9-neoGift from Tim Somerville[@bib56]MSCV-PML-RARAGift from Eric So[@bib12]MSCV-MOZ-TIF2Gift from Brian Huntly[@bib22]pLKO.1-puro Empty Vector Control Plasmid DNASigma-AldrichCat\#SHC001**Biological Samples**Primary human AML samplesManchester Cancer Research Centre Tissue BiobankN/A**Chemicals, Peptides, and Recombinant Proteins**Polyinosinic-polycytidylic acid (pIpC)GE HealthcareCat\#C27-4732-01TRIzolThermo Fisher ScientificCat\#15596026Micrococcal nuclease (MNase)Roche Applied ScienceCat\#10107921001PNKNew England BiolabsCat\#M0201STNF-αPeproTechCat\#315-01A-5IL-6BiolegendCat\#575706G-CSFBiolegendCat\# 578602TPOBiolegendCat\#593306IL-3BiolegendCat\#575506SCFBiolegendCat\#579708GM-SCFBiolegendCat\#576306SuperSignal West Dura Extended Duration SubstrateThermo Fisher ScientificCat\#34075**Critical Commercial Assays**Ambion WT Expression kitAmbionCat\#4491974Affymetrix, WT Terminal and Control KitsAffymetrixCat\#901524Lexogen Catabolic kitLexogenCat\#062.24Lexogen QuantSeq 3′ mRNA-Seq Library Prep KitLexogenCat\#015.24NEBNext® Multiplex Small RNA Library Prep SetNew England BiolabsCat\#E7580SEpicenter Ribo-zero kitEpicenterCat\#MRZH116SENSE Total RNA-Seq Library Prep KitLexogenCat\#009.0815% Novex TBE-Urea GelThermo Fisher ScientificCat\#EC6885BOXBolt 4-12% Bis-Tris Plus GelThermo Fisher ScientificCat\#NW04120BOX**Deposited Data**AffymetrixThis paperE-MTAB-6783; E-MTAB-7782m^6^A meRIP-Seq datasetsThis paperE-MTAB-6791; E-MTAB-7783RIBO-seqThis paperE-MTAB-7785SLAM-seqThis paperE-MTAB-7784**Experimental Models: Cell Lines**THP-1ATCCCat\#TIB-202NOMO-1DSMZCat\#ACC 542**Experimental Models: Organisms/Strains***Ythdf2*^fl/fl^ mice[@bib23]N/A*Vav-iCre* miceThe Jackson LaboratoryStock No: 008610*Mx1-Cre* miceThe Jackson LaboratoryStock No: 003556NOD *scid* gammaThe Jackson LaboratoryStock No: 005557**Oligonucleotides**HPRT1 Taqman Gene Expression AssaysThermoFisher ScientificCat\#Hs02800695_m1YTHDF2 Taqman Gene Expression AssaysThermoFisher ScientificCat\#Hs00212357_m1shRNA KD1, 5′-TACTGATTAAGTCAGGATTAA-3′Sigma-AldrichCat\#TRCN0000254410shRNA KD2, 5′- CGGTCCATTAATAACTATAAC −3′Sigma-AldrichCat\#TRCN0000254336shRNA CTL, 5′-TTCTCCGAACGTGTCACGTT-3′Custom cloned pLKO.1-puroN/A**Software and Algorithms**Bioconductor Limma Package[@bib52]<https://bioconductor.org/packages/release/bioc/html/limma.html>Bioconductor topGO packageBioconductor<https://bioconductor.org/packages/release/bioc/html/topGO.html>Bioconductor Simpleaffy package[@bib71]<https://bioconductor.org/packages/release/bioc/html/simpleaffy.html>Bioconductor arrayQualityMetrics package[@bib26]<http://bioconductor.org/packages/release/bioc/html/arrayQualityMetrics.html>deepTools package[@bib50]<https://deeptools.readthedocs.io/en/develop/>ConsensusPathDB (CPDB) software.[@bib25]<http://cpdb.molgen.mpg.de/>Bioconductor GVIZ package[@bib19]<https://bioconductor.org/packages/release/bioc/html/Gviz.html>stats R packageR project<http://www.R-project.org/>GraphPad Prism 6 softwareGraphPad Software, Inc.N/AHISAT2[@bib27]<https://ccb.jhu.edu/software/hisat2/index.shtml>MACS2[@bib75]<https://github.com/taoliu/MACS>HOMER<http://homer.ucsd.edu/homer/motif/>BEDtools[@bib49]<https://bedtools.readthedocs.io/en/latest/>SlamDunk<https://github.com/t-neumann/slamdunk>Kallisto[@bib5]<https://pachterlab.github.io/kallisto/>Xtail[@bib73]<https://github.com/xryanglab/xtail>DESeq2[@bib37]<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>RMAexpress software<http://rmaexpress.bmbolstad.com/>**Other**MethoCultTM M3434STEMCELL TechnologiesCat\#M3434MethoCultTM M3231STEMCELL TechnologiesCat\#M3231

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for reagents may be directed to, and will be fulfilled by the Lead Contact, Kamil Kranc (<kamil.kranc@qmul.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

All experiments on animals were performed under UK Home Office authorisation. All mice were on the C57BL/6 genetic background. *Ythdf2*^fl/fl^ mice were described previously ([@bib23]). *Vav-iCre* ([@bib6]), *Mx1-Cre* ([@bib31]), and NOD *scid* gamma mice were purchased from the Jackson Laboratory. All transgenic and knockout mice were CD45.2^+^. Congenic recipient mice were CD45.1^+^/CD45.2^+^.

### Human tissue & ethical approvals {#sec4.3.2}

Use of human tissue was in compliance with the ethical and legal framework of the United Kingdom's Human Tissue Act, 2004. Primary human AML samples were from Manchester Cancer Research Centre's Tissue Biobank (instituted with approval of the South Manchester Research Ethics Committee). Their use was authorized following ethical review by the Tissue Biobank's scientific sub-committee, and with the informed consent of the donor. Normal CD34^+^ HSPCs surplus to requirements were from patients undergoing autologous transplantation for lymphoma or myeloma. Their use was authorized by the Salford and Trafford Research Ethics Committee and, for samples collected since 2006, following the written informed consent of donors.

Method Details {#sec4.4}
--------------

### Flow cytometry {#sec4.4.1}

All BM and FL cells were prepared and analyzed as described previously ([@bib16], [@bib15], [@bib29], [@bib43], [@bib65]). BM cells were isolated by crushing tibias and femurs using a pestle and mortar. FL cells were prepared by mashing the tissue and passing through a 70μm strainer. Single cell suspensions from BM, FL or PB were incubated with Fc block and then stained with antibodies. For HSC and progenitor cell analyses, following incubation with Fc block, unfractionated BM cells were stained with lineage markers containing biotin-conjugated anti-CD4, anti-CD5, anti-CD8a, anti-CD11b, anti-B220, anti-Gr-1 and anti-Ter119 antibodies together with APC-Cy7-conjugated anti-c-Kit, Pacific Blue-conjugated anti-Sca-1, PE-conjugated anti-CD48 and PE-Cy7-conjugated anti-CD150 antibodies. Biotin-conjugated antibodies were then stained with PerCP-conjugated streptavidin. For analyses of differentiated cells, following incubation with Fc block, spleen or BM cell suspensions were stained with PerCP-conjugated anti-B220 and APC-Cy7-conjugated anti-CD19 antibodies for B cells; Pacific Blue-conjugated anti-CD11b and PE-Cy7-conjugated anti-Gr-1 for myeloid cells; APC-conjugated anti-CD8 antibodies and PE-conjugated anti-CD4 antibodies for T cells.

To distinguish CD45.2^+^-donor derived cells in PB or BM of transplanted mice, BV711-conjugated anti-CD45.1 and Pacific Blue-conjugated anti-CD45.2 antibodies were used. For HSC and progenitor staining in transplanted mice, APC-conjugated anti-c-Kit, and APC-Cy7-conjugated anti-Sca-1 were used; the remainder of the staining was as described above. For analyses of differentiated cells in BM of transplanted mice, myeloid cells were stained with PE-conjugated anti-CD11b, PE-Cy7-conjugated anti-Gr-1 and APC-conjugated anti-Ter119 for erythroid cells. Lymphoid cells were stained separately, as described above. PB of transplanted mice was stained with BV711-conjugated anti-CD45.1, Pacific Blue-conjugated anti-CD45.2, PE-conjugated anti-CD4 and-CD8a, PE-Cy7-conjugated anti-Gr-1, APC-conjugated anti-CD11b, and APC-Cy7-conjugated anti-CD19. TO-PRO-3 or DAPI were used for dead cell exclusion.

Flow cytometry analyses were performed using a LSRFortessa (BD). Cell sorting was performed on a FACSAria Fusion (BD).

### Colony forming cells (CFC) assays {#sec4.4.2}

CFC assays were carried out using MethoCultTM M3434 (STEMCELL Technologies) methylcellulose medium. Two technical replicates were used per each biological replicate in each experiment. Colonies were tallied at day 10. Human primary AML samples were enumerated after 7 days of culture in semisolid medium in the presence of recombinant IL-6, G-CSF and TPO (20ng/ml) using puromycin as the selectable marker.

### Leukemic transformation {#sec4.4.3}

c-Kit^+^ cells were prepared from FLs of 14.5 dpc embryos using c-Kit (CD117) enrichment with MACS columns (Miltenyi Biotec). 200,000 c-Kit^+^ cells were co-transduced with MSCV-Meis1a-puro and MSCV-Hoxa9-neo retroviruses. Transduced cells were subjected to three rounds of CFC assays in MethoCultTM M3231 (STEMCELL Technologies) supplemented with 20ng/ml SCF, 10ng/ml IL-3, 10ng/ml IL-6 and 10ng/ml GM-S*CF.* Colonies were counted 5 days after plating, and 2,000 cells were re-plated.

### Syngeneic transplantation assays {#sec4.4.4}

CD45.1^+^/CD45.2^+^ recipient mice were lethally irradiated using a split dose of 11 Gy (two doses of 5.5 Gy administered at least 4 hours apart) at an average rate of 0.58 Gy/min using a Cesium 137 GammaCell 40 irradiator.

For primary transplantations 200 LSKCD48^-^CD150^+^ HSCs (per recipient) sorted from BM of the donor mice were mixed with 200,000 support CD45.1^+^ BM cells and transferred into lethally irradiated CD45.1^+^/CD45.2^+^ recipients. For secondary transplantations 2,000-3,000 CD45.2^+^ LSK cells sorted from BM of primary recipients were mixed with 200,000 support CD45.1^+^ wild-type BM cells and re-transplanted. All recipient mice were culled and analyzed 16-20 weeks post-transplantation.

For transplantations of leukemic cells, 50,000-100,000 *Meis1*/*Hoxa9*-transduced c-Kit^+^ cells were transplanted into lethally irradiated CD45.1^+^/CD45.2^+^ recipient mice (together with 200,000 unfractionated support CD45.1^+^ wild-type BM cells). For secondary transplantation, 10,000 CD45.2^+^c-Kit^+^ cells sorted from BM of primary recipients were transplanted into lethally irradiated secondary CD45.1^+^/CD45.2^+^ recipient mice (together with 200,000 unfractionated support CD45.1^+^ wild-type BM cells).

### Xenotransplantation experiments {#sec4.4.5}

THP-1 cells transduced with CTL or KD lentiviruses were tail vein injected into non-irradiated 12 week-old female non-obese diabetic (NOD)/LtSz-severe combined immune-deficiency (SCID) IL-2Rγc^null^ (NSG) mice (1x10^6^ cells per 200 μL per mouse). Mice were killed one month after transplantation. For survival curve analyses, 10,000 or 1,000 cells per NSG mouse were injected. To assess human AML burden, cells were stained with anti-human PE-conjugated anti-CD45 and APC-conjugated anti-CD33.

### pIpC administration {#sec4.4.6}

Mice were injected intraperitoneally every other day with 300 μg pIpC (GE Healthcare) for a total of 6 doses, as previously described ([@bib16], [@bib15], [@bib29]).

### shRNA-mediated YTHDF2 knockdown {#sec4.4.7}

THP-1 cells were transduced with lentiviruses expressing shRNAs (shRNA KD1, 5′-TACTGATTAAGTCAGGATTAA-3′ \[TRCN0000254410, Sigma-Aldrich\]; shRNA KD2, 5′- CGGTCCATTAATAACTATAAC −3′ \[TRCN0000254336, Sigma-Aldrich\]; and shRNA CTL, 5′-TTCTCCGAACGTGTCACGTT-3′; GE Healthcare). Selection of efficiently transduced cells was achieved by treatment with puromycin (2 μg/mL final concentration).

### Cell proliferation, cell death and cell differentiation analyses {#sec4.4.8}

Lentivirus-transduced THP-1 were seeded at 15x10^4^/mL after puromycin selection. Viable cells were counted by trypan blue exclusion at the indicated time points. To analyze cells undergoing apoptosis, cells were suspended in binding buffer containing Annexin V-PE and DAPI. To assess myeloid differentiation, cells were stained with PE-conjugated anti-CD14 and APC-conjugated anti-CD11b antibodies.

### Primary human AML patient derived samples {#sec4.4.9}

For western blotting shown in [Figure 1](#fig1){ref-type="fig"}B, the following samples were used: 70 (karyotype 46,XY,del(7)(q22q32)\[20\]), 104 (karyotype 46,XX,t(6;9;11)(p2?1;p22;q23)\[6\]/45,idem,der(15)t(15;17)(p11.2;q11.2),-17\[4\] \[variant of t(9;11)\]0, 108 (karyotype 46,XX,t(6;11)(q27;q23)\[10\]), 149 (karyotype 46,XX,t(15;17)(q22;q11.2)\[7\]/46,sl,-6,add(16)(q12),+mar\[3\]/46,XX\[3\]), 163 (karyotype 45,X,-Y,t(8;21)(q22;q22)\[8\]/46,XY\[2\]), 191 (karyotype 46,XX \[20\]), 205 (karyotype 44,XX,add(3)(p25),-5,-7\[12\]), 419 (karyotype 46,XX,t(1;22)(p21;p11.2),ins(10;11)(p12;q23q1?4)\[10\] nb variant of t(10;11) MLL-MLLT10 fusion), 539 (karyotype 46,XY \[20\]), 685 (karyotype 46,XX,t(6;9)).

For CFC assays shown in [Figures 2](#fig2){ref-type="fig"}L and 2M, the following samples were used: 160 (AML1) (karyotype 46,XX,t(9;11)(p22;q23),der(21;22)(q10;q10),+der(21;22)\[cp10\]; MLL-MLLT3 rearrangement; clonal evolution with add(Xp); add(4q); add(7q); +21 at relapse), 292 (AML2) (karyotype 46,XX,t(15;17); PML-RARA rearrangement \[no cyto report available\]), 251 (AML3) (karyotype 46,XY,t(6;9)(p22;q34)\[9\]/46,XY,der(6)t(6;9),der(9)t(6;9)del(9)(q21q34)\[2\]).

### Western blotting {#sec4.4.10}

Proteins extracted from CTL, KD1 and KD2 THP-1 cells were subjected to SDS--PAGE (Bolt 4%--12% Bis-Tris Plus Gel, ThermoFisher Scientific, NW04120BOX) and then transferred onto a polyvinylidene fluoride membranes. Membranes were blocked in 10% milk-PBST (PBS with 0.1% Tween20) and probed with anti-YTHDF2 (1:5000, ON at 4°C) and anti- Histone3 (1:5000, 1h at room temperature). After incubation with appropriate horseradish peroxidase-coupled secondary antibody, proteins were detected with SuperSignal West Dura Extended Duration Substrate (ThermoFisher Scientific, 34075) and acquired on the Amersham Imager 600 (GE Healthcare life Sciences).

### Affymetrix {#sec4.4.11}

RNA extraction from *Meis1*/*Hoxa9*-transduced c-Kit^+^ cells was performed using TRIzol (Thermo Fisher Scientific). Total RNA was used to synthesize Biotinylated cDNA with the Ambion WT Expression kit (Ambion, 4491974). cDNA was fragmented and labeled with the Affymetrix, WT Terminal and Control Kits (Affymetrix, 901524) and then hybridized for 16 hours at 45**°**C on a GeneChip Mouse Gene 2.0 ST Array. The chip was later washed and stained with the Affymetrix Fluidics Station 450. Data were processed and analyzed using the Bioconductor Limma Package ([@bib52]). Samples were normalized using the rma function and differential expression was assessed using linear modeling. Log2-fold-changes and moderated t-statistics were calculated using the contrasts.fit function. To determine the gene ontology (GO) enrichment of differentially expressed genes, we used the topGO R package. Fisher's exact test was used to assess enrichment for the biological process ontology.

### Analyses of YTHDF2 expression in human AML samples {#sec4.4.12}

To generate [Figure 1](#fig1){ref-type="fig"}A the following publicly available datasets were used: [GSE10358](ncbi-geo:GSE10358){#intref0100}, [GSE52891](ncbi-geo:GSE52891){#intref0105}, [GSE61804](ncbi-geo:GSE61804){#intref0110}, [GSE68833](ncbi-geo:GSE68833){#intref0115}, [GSE12417](ncbi-geo:GSE12417){#intref0120}, [GSE13159](ncbi-geo:GSE13159){#intref0125}, [GSE15061](ncbi-geo:GSE15061){#intref0130}, [GSE15434](ncbi-geo:GSE15434){#intref0135}, [GSE16015](ncbi-geo:GSE16015){#intref0140}, [GSE19577](ncbi-geo:GSE19577){#intref0145}, and [GSE22845](ncbi-geo:GSE22845){#intref0150} ([@bib1], [@bib17], [@bib18], [@bib28], [@bib41], [@bib40], [@bib42], [@bib47], [@bib59], [@bib60]). Exclusion criteria included datasets with less than 20 samples, samples with undefined tissue of origin, cell type and karyotype, in addition to RAEB samples. Only BM samples, with a total of 1732 samples were retained for further analysis. The Simpleaffy package from Bioconductor was used to extract quality measurement of microarrays ([@bib14], [@bib71]). RNA degradation was assessed based on 3′ to 5′ ratio of *GAPDH* and *ACTNB* genes. Samples with NUSE \< 1.05 and relative log expression (RLE) \< 0.15 were excluded from further analysis ([@bib39]). The retained samples were assessed for their homogeneity using the Bioconductor arrayQualityMetrics package ([@bib26]). Low quality RNA and outlier samples were excluded, while high quality samples retained after quality control were background corrected and normalized using RMAexpress software (<http://rmaexpress.bmbolstad.com/>). Pairwise comparisons between each karyotype and control were performed using Student's t test.

### m^6^A meRIP-Seq {#sec4.4.13}

m^6^A meRIP-Seq library preparation was performed as previously described ([@bib35]) from *Ythdf2*^CTL^ pre-leukemic cells. Three biological replicates for each condition were used. Reads were aligned to the mouse or human reference genome using HISAT2 ([@bib27]) and peaks were called using MACS2 ([@bib75]). To analyze the distribution of peaks along the transcripts, bedgraph files were converted to bigWig format and used as input for the computeMatrix function of the deepTools package ([@bib50]). Motif enrichment was done using HOMER selecting a motif length of 6 nucleotides. Background regions were generated by shuffling peaks along the transcriptome using the shuffleBed tool from the BEDtools suite ([@bib49]). Network analysis was performed using the ConsensusPathDB (CPDB) software ([@bib25]). For gene set enrichment analysis (GSEA), the [GSE76008](ncbi-geo:GSE76008){#intref0160} dataset ([@bib44]) was used to rank genes according to the engraftment potential of pre-leukemic cells. The GVIZ bioconductor package was used for peak visualization ([@bib19]).

Correlation with YTHDF2 was measured to determine robust YTHDF2 targets after the knockout ([@bib38]). Briefly, Pearson correlation between YTHDF2 and the identified YTHDF2 targets was calculated using the 1732 AML samples previously described. Correlation significance was measured using parametric test with length (genes)-2 degrees of freedom (cor.test function, stats package, R project, <http://www.R-project.org/>), and adjusted for multiple comparisons using Benjamini & Hochberg method ([@bib3]). Genes with negative coefficients and adjusted p value \< 0.05 were considered strong targets of YTHDF2.

### SLAM-seq {#sec4.4.14}

SLAM-seq libraries were prepared using the Lexogen catabolic kit (cat. no. 062.24) and the Lexogen QuantSeq 3′ mRNA-Seq Library Prep Kit FWD for Illumina (cat. no. 015.24) in both cases following manufacturers' instructions. S4U was used at 2.9 μM, as determined by the cell viability titration assay. Medium with 4SU was used for pre-leukemic cells labeling for 12 hours and was later replaced with 4SU-free medium (time 0). Cells were collected immediately after medium change and at 1, 3, and 9 hours. Libraries were sequenced using an Illumina HiSeq platform in a 50 bp single-end mode. Biological triplicates for both *Ythdf2*^*CTL*^ and *Ythdf2*^*cKO*^ pre-leukemic cells were used to generate the different libraries sets. SLAM-seq libraries were analyzed as previously described ([@bib20]). Briefly, T to C conversion rates were obtained using the SlamDunk pipeline. Conversion rates across different time points were normalized to time 0 for each gene and were used to fit a first order decay reaction with the R stats package nls function.

### RIBO-seq {#sec4.4.15}

RIBO-seq libraries were prepared as previously described ([@bib51]). Briefly, pre-leukemic cells were lysed with CaCl~2~ 4 mM, MgCl 10 mM, K-HEPES pH 7.2 25 mM, KOAc 200 mM and NP-40 1%. The lysate was cleared from cell debris, diluted 1:1 in water, and digested with MNase 10 μg/ml for 30 minutes at 37°C. Digested RNA was extracted with QIAzol and later treated with PNK (NEB) for 30 minutes at 37°C. To isolate ribosome-protected mRNA fragments (RPFs), the PNK-treated RNA was resolved on a 15% Novex TBE-Urea Gel (EC6885BOX), and RPFs 25 to 40 nucleotides long were excised and purified. Libraries were then prepared using the NEBNext® Multiplex Small RNA Library Prep Set for Illumina following manufacturer's instructions. For input controls, total RNA was extracted from the pre-leukemic cell lysates before MNase digestion using QIAzol. Samples were then depleted of ribosomal RNA using the Epicenter Ribo-zero kit (cat. no. MRZH116), and libraries were generated using the SENSE Total RNA-Seq Library Prep Kit (cat no. 009.08) following manufacturer's instructions. Libraries were sequenced with the Illumina HiSeq platform in a 50 bp single-end mode. Biological triplicates were used to generate libraries for both *Ythdf2*^*CT*L^ and *Ythdf2*^*cKO*^ pre-leukemic cells. For the RIBO-seq analysis, we used Kallisto ([@bib5]) to obtain read counts per gene for the RPF and mRNA libraries. Read counts were then used to calculate the differential translational efficiency between *Ythdf2*^*CT*L^ and *Ythdf2*^*cKO*^ pre-leukemic cells with Xtail ([@bib73]). To estimate the relative translational efficiency for genes in each condition, we compared RPF and mRNA read counts using DESeq2 ([@bib37]).

Data and Software Availability {#sec4.5}
------------------------------

### Accession {#sec4.5.1}

Affymetrix, m^6^A meRIP-Seq, RIBO-seq and SLAM-seq datasets were deposited in ArrayExpress under the following accession numbers: E-MTAB-6783, E-MTAB-7782, E-MTAB-6791, E-MTAB-7783, E-MTAB-7785 and E-MTAB-7784. Data from NOMO-1 and MA9.3ITD human cell lines were obtained from previously published work ([@bib57]) through the following accession number: [GSE87190](ncbi-geo:GSE87190){#intref0170}.

Quantification and Statistical Analysis {#sec4.6}
---------------------------------------

Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc.). P values were calculated using a two-tailed Mann--Whitney U test unless stated otherwise. Kaplan-Meier survival curve statistics were determined using the Log-rank (Mantel Cox) test.
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